Vendor Intelligence Report: The Naughty Needle

Published 13 Jun 2026. 18-page investigative report on who is behind The Naughty Needle: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

The Naughty Needle is a new, polished GLP-1/GIP-focused vendor with a narrow but constructive independent test record. Across 2 Finnrick lab tests the overall pass rate is 100% (2 pass / 0 fail). The signal is entirely Tirzepatide: useful for buyers shortlisting that product, but not yet evidence for Sema-1/Semaglutide, Reta-3/Retatrutide, Cagralintide, or the wider catalog. The report also notes that a two-test record can move differently under stricter scoring thresholds, so current-batch verification still matters.

The public trail places the vendor in the mid-2025 cohort: one Naughty Needle domain was still parked in a July Wayback capture before the active TNN Peptides storefront appeared. That short history is not disqualifying, but it shifts diligence toward canonical-channel checks. The investigation separates the Instagram brand, legacy domain, active storefront, and absence of a verified reseller or anti-counterfeit protocol without treating brand confusion as proof of impersonation.

The operational story is more interesting than the storefront. A New Jersey marketing agency is documented in the site footer, its portfolio, and a shared technical footprint; the report treats that as a strong agency relationship, not proof of ownership. Vendor COAs route through Freedom Diagnostics Testing, whose Franklin, Tennessee address and named chemist overlap with Limitless Medical Laboratories, while ISO/IEC 17025 accreditation remains unverified. Meanwhile, TNN Peptides LLC was not found in the searched corporate registries.

Promotion risk is comparatively muted: the X/web sweep found no coupon, referral, or promoter network, and one Instagram discount lead was ruled unrelated. The buyer posture is therefore product-specific rather than blanket: credible early Tirzepatide signal, medium transparency and lab-accreditation concerns, and insufficient independent evidence for the rest of the catalog.

Inside the full report:

  • Per-product Finnrick pass/fail summary, sparkline, methodology-divergence chart, and Appendix A lab data for the covered Tirzepatide record
  • Domain chronology using WHOIS and Wayback records for thenaughtyneedle.com and tnnpeptides.com
  • Eighty6 footer, portfolio, and shared-infrastructure analysis with ownership caveats
  • Freedom Diagnostics COA review with Limitless Medical Laboratories address and personnel overlap
  • Corporate-registry absence trail across California, Tennessee, and OpenCorporates
  • Affiliate and promotion sweep including X/web results and the false-positive discount-code lead

Risk assessment

  • Corporate transparency and legal-recourse risk — medium: TNN Peptides LLC was not found in California, Tennessee, or OpenCorporates searches; domain ownership is privacy-shielded.
  • COA-lab accreditation uncertainty — medium: Vendor COAs are issued by Freedom Diagnostics Testing; the materials do not verify ISO/IEC 17025 accreditation despite LC-MS/MS claims and Limitless Medical Laboratories overlap.
  • Brand-confusion and canonical-channel risk — medium: The Instagram trail surfaced thenaughtyneedle.com while the active shop is tnnpeptides.com; no authoritative official-channel/reseller list or anti-counterfeit protocol was documented.
  • Limited independent testing coverage outside Tirzepatide — medium: Finnrick has only 2 tests, both pass, for Tirzepatide; Sema-1/Semaglutide, Retatrutide/Reta-3, Cagralintide and other catalog items lack Finnrick coverage in the supplied record.